MedTrace Logo

Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment

NCT04982484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-07-29

No results posted yet for this study

Summary

AMD (age-related macular degeneration), is the leading cause of blindness in individuals over the age of 55. There is no cure for wet-AMD but anti-VEGF treatments significantly minimize the vision loss over time. To study the correlation between anti-VEGF injection bevacizumab (Lucentis), visual acuity, macular thickness and last but not least reading speed in wet-AMD patients.

The study was conducted on 50 eyes of 50 wet-AMD patients. Subjects were monthly treated with an intra-vitreal Lucentis injection for 3 months; further injections were given when a loss of 5 or more letters of visual acuity was observed and/or when the retinal thickness in the affected macular area increased by 100 µm. In addition to a full ophthalmological examination reading speed was investigated via the Radner reading chart before and 3 months after treatment. The collected data was analyzed using paired t-tests.

Conditions

  • Ophthalmopathy
  • Wet Macular Degeneration

Sponsors & Collaborators

  • University of Pecs

    collaborator OTHER

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Georges Jr Hayek, MD · CHR Metz Thionville Hopital de Mercy

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-01
Primary Completion
2013-06-01
Completion
2013-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982484 on ClinicalTrials.gov